Hu8F4 in Treating Patients With Advanced Hematologic Malignancies
Status:
Recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of anti-PR1/HLA-A2 monoclonal
antibody Hu8F4 (Hu8F4) in treating patients with malignancies related to the blood
(hematologic). Monoclonal antibodies, such as Hu8F4, may interfere with the ability of cancer
cells to grow and spread.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
National Cancer Institute (NCI) The Leukemia and Lymphoma Society